(Q24201799)

1

object named as

Winfried Häuser

0 references

Brian Walitt

5

object named as

Brian Walitt

0 references

Nurcan Üçeyler

4

object named as

Nurcan Üçeyler

0 references

author name string

Sera Tort

Cochrane Database of Systematic Reviews

3

0 references

publication date

31 January 2013

0 references

published in

0 references

cites work

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

An open clinical trial of venlafaxine treatment of fibromyalgia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Effective treatment of fibromyalgia comorbid with premenstrual dysphoric disorder with a low dose of venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Venlafaxine Treatment of Fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Minimal clinically important difference in the fibromyalgia impact questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Prevalence of fibromyalgia: a survey in five European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Was sind die Kernsymptome des Fibromyalgiesyndroms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Validation of the Fibromyalgia Survey Questionnaire within a cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Milnacipran for treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Fibromyalgia syndrome module at OMERACT 9: domain construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Anti-depressants and centrally active agents for fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Fibromyalgia syndrome: Prevalence, pharmacological and non-pharmacological interventions in outpatient health care. An analysis of statutory health insurance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Etiology and pathophysiology of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

The development of fibromyalgia--I: examination of rates and predictors in patients with rheumatoid arthritis (RA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

Comment on the 1990 American College of rheumatology criteria for fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

7 January 2021

A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

7 January 2021

Candidate gene studies of fibromyalgia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

7 January 2021

Systematic review: Placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

7 January 2021

Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010292

7 January 2021

10.1002/14651858.CD010292

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_d72yhs5jtveiffhsls26n4etom

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d72yhs5jtveiffhsls26n4etom

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23440848

1 reference

Consolidated OpenCitations Corpus – April 2017